actinic keratosis

Type: Keyphrase
Name: actinic keratosis
First reported Oct 24 2014 - Updated Oct 24 2014 - 1 reports

Figure. The crusted lesions on the patient’s scalp.

Case presentationA 78-year-old man presents with multiple crusted irritable lesions on his scalp that he says have been slowly worsening over the past year (Figure). The lesions are irritable, causing him to pick and scratch. He has generalised sun damage ... [Published Medicine Today - Oct 24 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 2 reports

Actinic Keratosis Treatment Market - Global Segment and Forecasts Up to 2020

Albany, NY -- (SBWIRE) -- 10/23/2014 -- Presence of thick, crusty or scaly patches on the skin surface indicating premalignant condition is referred as actinic keratosis. People who are commonly exposed to sun light are at higher risk of actinic keratosis. ... [Published Good Day Sacramento - Oct 23 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Suburban Dermatologist Convicted Of Cheating Medicare And Private Insurers Of $2.6 Million In Health Care Fraud Scheme

CHICAGO - A dermatologist in west suburban Lombard was convicted today of defrauding Medicare and private health insurers by submitting false claims for more than 800 patients resulting in losses totaling more than $2.6 million. The defendant, DR. ROBERT ... [Published Noodls - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Baobab oil, the natural choice for healthy skin

Baobab oil is an excellent skin moisturizer, which absorbs quickly into the skin without clogging pores.Baobab oil is an excellent skin moisturizer, which absorbs quickly into the skin without clogging pores. It leaves the skin feeling soft and moisturized. ... [Published Get It Durban - Oct 20 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents

The present invention provides NO-releasing NONOate(nitrogen bound)sulfonamide-linked-coxib anti-cancer agents, having the structure of Formula (I): wherein R1, X, L, R2, R3, R4, and Z are as defined in the detailed description; pharmaceutical compositions ... [Published Free Patents Online - Oct 14 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 4 reports

Biofrontera can look to expand Ameluz use, says Cenkos

Broker Cenkos said skin-cancer focused firm () can look to expand the use for its Ameluz treatment to diseases like basal cell carcinoma after a successful US clinical study.The firm published compelling results on Thursday from the phase III trial, ... [Published Proactive Investors.co.uk - Oct 02 2014]
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

"Pantec Biosolutions AG - Product Pipeline Analysis, 2014 Update" Now Available at Fast Market Research

Boston, MA -- (SBWIRE) -- 09/26/2014 -- Pantec Biosolutions AG (Pantec) is a transdermal drug delivery solution provider. The company develops transdermal drug delivery products using laser microporation technology. Its products include infertility patches, ... [Published Crawford Financial Planning - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Biofrontera AG: First Ameluz® sales in Central Eastern European region

Biofrontera AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Leverkusen, 6 August 2014 - Biofrontera (AIM/FSE:B8F), the European biopharmaceutical company, has started ... [Published PR inside - Sep 23 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 2 reports

Tampa Bay Specialist Offers Two-Part Treatment for Pre-Cancerous Actinic Keratosis

Dr. Jeffrey Hunt Provides Non-Surgical Levulan(R) Kerastick(R) and BLU-U(R) Treatments to Eliminate Actinic Keratosis Skin Lesions, Which Can Potentially Develop Into Skin Cancer; This Is Also Called PDT or Photodynamic TherapyTAMPA BAY, FL--(Marketwired ... [Published Scottrade - Sep 18 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

New Data Presented at WCCS Confirm High Long-term Efficacy of Picato® in Patients with Actinic Keratosis

Ballerup, Denmark (ots/PRNewswire) – Not for US media The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis New data from the international FIELD Study Repeat presented ... [Published PRESSEMITTEILUNGEN - Sep 04 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Biofrontera's domestic sales remain strong

German biotech Biofrontera ( LON:B8f ) is confident of hitting its target of upping domestic sales by around 30% this year. Sales in Germany increased by 21% in the first half of the year, the company revealed, as it posted interim figures. Half-year ... [Published Proactiveinvestors United Kingdom RSS feed - Aug 29 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Kinex announces allowance of IND application for KX2-391 ointment by USFDA

Kinex Pharmaceuticals has announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the ... [Published PBR - News - Jul 25 2014]

Quotes

"We have previously commented that we believe actinic keratoses is just the beginning for Ameluz and now with the solid data for this indication presented, the company can look to expand the use of Ameluz to diseases such as basal cell carcinoma (a rapidly growing market)."
"Achievement of our revenue expectations for the full year will therefore be dependent on the successful conclusion of a contract with a US-based distribution partner in respect of which Biofrontera would anticipate a large down-payment. The probability that this may still be implemented this year, cannot currently yet be estimated,” the company said. "
Hermann Luebbert, Biofrontera ’s chief executive, said: "We are looking forward to the opportunity to discuss our dossier for the combination of Ameluz and BF-RhodoLED with the FDA.  "
" We have some major milestones in the near future to help us build on Biofrontera's gr owth potential and ultimately to deliver shareholder value. Biofrontera looks to further increase revenues in 2015 by a ccelerating sales of Ameluz® in more European countries and extending the indication to also treat Basal Cell Carcinoma as well as working towards achieving FDA approval in the US, thereby opening up the North American market for sales in 2016. We are looking forward to UK investors joining Biofrontera on its exciting next steps in becoming an international pharmaceutical company."

More Content

All (33) | News (28) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Figure. The crusted lesions on the patient’s sc... [Published Medicine Today - Oct 24 2014]
IGI Laboratories' (IG) CEO Jason Grenfell-Gardn... [Published Seeking Alpha - Oct 24 2014]
Actinic Keratosis Treatment Market - Global Seg... [Published Good Day Sacramento - Oct 23 2014]
Actinic Keratosis Treatment Market - Global Seg... [Published CW 50 Detroit - Oct 23 2014]
Suburban Dermatologist Convicted Of Cheating Me... [Published Noodls - Oct 21 2014]
Baobab oil, the natural choice for healthy skin [Published Get It Durban - Oct 20 2014]
Reset Your Face -- In-Depth Interview [Published Medical Breakthroughs - Oct 20 2014]
No-releasing nonoate(nitrogen-bound)sulfonamide... [Published Free Patents Online - Oct 14 2014]
Cucumber heals acid burnt eyes, ulcers, viral i... [Published The Guardian Nigeria - Oct 09 2014]
The challenge of pigmented lesions [Published Australian Doctor - Oct 07 2014]
Biofrontera can look to expand Ameluz use, says... [Published Proactive Investors.co.uk - Oct 02 2014]
Biofrontera reports excellent res... [Published TrustNet - Oct 02 2014]
Biofrontera reports excellent results from Amel... [Published MoneyAM - Oct 02 2014]
Ad hoc: Biofrontera AG: Clinical program for US... [Published Pettinga Financial Advisors - Oct 02 2014]
BIOFRONTERA : Clinical program for US approval ... [Published 4 Traders - Oct 02 2014]
"Pantec Biosolutions AG - Product Pipeline Anal... [Published Crawford Financial Planning - Sep 26 2014]
WAGRE Fraxel Laser Clinic Reports the Anti-Agin... [Published Digital Journal - Sep 24 2014]
Biofrontera AG: First Ameluz® sales in Central ... [Published PR inside - Sep 23 2014]
Reset you face to avoid cancer [Published KLAS-TV - Sep 19 2014]
Tampa Bay Specialist Offers Two-Part Treatment ... [Published Scottrade - Sep 18 2014]
Tampa Bay Specialist Offers Two-Part Treatment ... [Published Marketwire - Breaking News Releases - Sep 18 2014]
Reset Your Face [Published Texomashomepage.com - Sep 15 2014]
New Data Presented at WCCS Confirm High Long-te... [Published PRESSEMITTEILUNGEN - Sep 04 2014]
Biofrontera's domestic sales remain strong [Published Proactiveinvestors United Kingdom RSS feed - Aug 29 2014]
Biofrontera confident ahead of FDA meeting on A... [Published Proactiveinvestors United Kingdom RSS feed - Aug 21 2014]
Biofrontera makes first Ameluz sales in Slovenia [Published BioPortfolio - Aug 06 2014]
Kinex announces allowance of IND application fo... [Published PBR - News - Jul 25 2014]
Kinex Pharmaceuticals Announces Allowance of th... [Published PR Newswire: Health - Jul 24 2014]
Research and Markets: Actinic Keratosis Pipelin... [Published Business Wire Health News - Jul 01 2014]
Skin cancer drug group Biofrontera makes steady... [Published Proactiveinvestors United Kingdom RSS feed - Jun 03 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Tampa Bay Specialist Offers Two-Part Treatment ... [Published Marketwire - Breaking News Releases - Sep 18 2014]
Dr. Jeffrey Hunt Provides Non-Surgical Levulan(R) Kerastick(R) and BLU-U(R) Treatments to Eliminate Actinic Keratosis Skin Lesions, Which Can Potentially Develop Into Skin Cancer; This Is Also Called PDT or Photodynamic Therapy ...
New Data Presented at WCCS Confirm High Long-te... [Published PRESSEMITTEILUNGEN - Sep 04 2014]
Ballerup, Denmark (ots/PRNewswire) – Not for US media The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis New data from the international FIELD Study Repeat presented ...
Kinex announces allowance of IND application fo... [Published PBR - News - Jul 25 2014]
Kinex Pharmaceuticals has announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the ...
Kinex Pharmaceuticals Announces Allowance of th... [Published PR Newswire: Health - Jul 24 2014]
BUFFALO, N.Y., July 24, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third ...
Research and Markets: Actinic Keratosis Pipelin... [Published Business Wire Health News - Jul 01 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/smn5g3/actinic_keratosis) has announced the addition of the "Actinic Keratosis Pipeline Highlights - 2014 Update" report to their offering. The latest report Actinic ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.